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Summary 
Background: The study was undertaken to assess the in -
fluence of functional -308G/A TNF-a (rs 1800629) and
-174G/C IL-6 (rs1800795) promoter polymorphisms on
the therapeutic response to etanercept, a TNF-a blocker, in
patients with rheumatoid arthritis (RA). 
Methods: Seventy-three patients suffering from active RA
were studied, at baseline and 6 and 12 months after ther-
apy. The therapeutic response was estimated according to
the European League Against Rheumatism response cri -
teria. Patients were genotyped for -308G/A TNF-a and
-174G/C IL-6 polymorphisms by the PCR-RFLP method,
and the influence of genotype on etanercept response was
assessed. 
Results: No difference in the percentage of responders
(patients who had DAS28 improvement > 1.2) between
patients with the TNF-α -308GG and GA and AA genotype
was detected after 6 and 12 months of treatment. After 12
months of treatment the percentage of responders was sig-
nificantly increased in patients with the IL-6 -174GG geno-
type compared with those with the GC or CC genotype
(p=0.006 by Chi-square test). Evaluation of the patients
Kratak sadr`aj
Uvod: Geneti~ki faktori su zna~ajni za predvi|anje ishoda
le~enja bolesnika sa reumatoidnim artritisom (RA). Cilj stu -
dije bio je da se ispita uticaj -308G/A TNF-a (rs 1800629) i
-174G/C IL-6 (rs1800795) promotorskih polimorfizama na
terapijski odgovor na etanercept. 
Metode: U studiju su bila uklju~ena 73 pacijenta sa aktiv -
nim RA. Terapijski odgovor je procenjivan posle 6 i 12 me -
seci terapije po kriterijumima Evropske lige protiv reuma -
tizma. Genotipizacija pacijenata za polimorfizme -308G/A
TNF-a i -174G/C IL-6 ura|ena je PCR-RFLP meto dom i
procenjivan je uticaj genotipova na odgovor na eta nercept. 
Rezultati: Nije bilo razlike u procentu respondera (pacijen-
ti kod kojih se DAS28 popravio > 1,2) izme|u pacijenata
sa TNF-α -308GG, GA i AA genotipom ni posle 6 ni posle
12 meseci tretmana. Posle 12 meseci le~enja procenat
respondera je bio zna~ajno ve}i kod pacijenata sa IL-6
-174GG u odnosu na pacijente sa GC ili CC genotipom
(p=0,006, c2 test). Pore|enje pacijenata prema kombi -
novanim IL-6/TNF-a genotipovima pokazalo je da je IL-6
-174GG / TNF-a -308GG genotip u~estaliji kod respon-
dera u odnosu na druge kombinovane genotipove
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Introduction
Anti-TNF therapy has made a significant contri-
bution to the treatment of patients with rheumatoid
arthritis (RA). However, these agents are expensive
and have significant side effects. Favorable therapeu-
tic response was detected in 50%–70% of patients
treated with TNF-a blockers. In the remaining
30%–50% of patients treatment is usually aborted
because of the ineffectiveness or side effects of
TNF-a inhibitors (1). This is why patient selection is
important for effective application of this drug. In
addition to clinical parameters, it is necessary to know
other predictors of treatment response to anti-TNF-a
agents. In recent years, pharmacogenetic research
has been focused on finding genetic markers that will
be important for forecasting therapeutic outcome of
the biological drugs (2).
Considering the central role that TNF-a and IL-
6 play in the pathogenesis of RA (3, 4), it is possible
that different production of these cytokines may not
only affect the natural course of the disease, but also
the response to therapy such as TNF-a blockade.
Several genetic polymorphisms in the promoter of
the IL-6 and TNF-a genes associated with different
constitutive and induced production of these cyto -
kines were reported. The genetic variant at position
-308G/A (rs 1800629) of the gene encoding TNF-a
was found to have functional effects on the gene tran-
scriptional activity. The rare TNF2 allele (-308A) is
associated with higher TNF-a production (5). Simi -
larly, the single nucleotide polymorphism (SNP) at
position -174G/C of the IL-6 promoter (rs1800795)
has been found to alter in vitro the transcriptional
response to stimuli such as LPS and IL-1 in HeLa cells
(6). Carriage of the C allele at this SNP has been
shown to correlate with higher serum concentrations
of IL-6 in general populations (7) and in RA patients
(8). 
Several studies and meta-analyses have ana -
lysed the association between -308G/A TNF-a and
-174G/C IL-6 SNPs and RA activity and response
to TNF-a blockers in RA. An association between
the -308G/A TNF-a polymorphism and treat ment
res ponse was found in certain studies (9–14) while
two meta-analyses did not confirm this association
(15, 16). Also, there have been conflicting reports of
the effect of the IL6 -174G/C polymorphism on anti-
TNF response in RA. In the study conducted by
Cessareli et al. (17), no differences in the proportions
of responders between IL-6 -174G/C genotypic
groups was demonstrated, while in our previous study
(18) and in a meta-analysis (19) combining results
from 199 Spanish RA patients with data from our pre-
vious study, association between the IL-6 -174G/C
polymorphism and the response to TNF-a blockers
was found. However, it is known that TNF-a stimu-
lates production of IL-6 (20) and that reduction of
IL-6 serum concentration in RA patients treated with
TNF-a blockers is a downstream effect (21), suggest-
ing that interactions between TNF-a and IL-6
cytokine genes may influence disease activity and the
clinical response to TNF-a blockade. In a previous
study, we found that the -174G/C IL-6 gene pro moter
polymorphism influences the clinical response to
etanercept (18). The aim of this study was to exam-
ine the possible influence of -308G/A TNF-a poly-
morphism and its interaction with -174G/C IL-6 poly-
morphism on the response to etanercept.
Materials and Methods
Patients and treatment protocol
The study was conducted in a cohort of 73 con-
secutive Caucasian patients with active RA refractory
to conventional disease-modifying antirheumatic
drugs (DMARDs). All patients who started to receive
etanercept therapy in the years 2009 and 2010 were
included in the study. Before starting treatment with
etanercept, tuberculin skin test and chest X-ray were
performed in all patients and both active and inactive
(‘latent’) tuberculosis were excluded. Also, in all
patients testing for HBC and HCV infection was ne g -
ative. The patients fulfilled the 1987 American
College of Rheumatology (formerly the American
Rheumatism Association) criteria for the classification
of RA (22) and were enrolled at the Institute of
according to their combined IL-6/TNF-a genotypes showed
that patients with the IL-6 -174GG / TNF-a -308GG geno-
type were more frequent among the responders compared
to those with other combined genotypes (p=0.022 by Chi-
square test). More precisely, all patients with the combined
IL-6 -174GG / TNF-a -308GG genotype were responders
after 12 months of etanercept treatment.
Conclusions: The study suggests that patients who are
genetically low TNF-a and IL-6 producers are the best
responders to etanercept therapy.
Keywords: etanercept, pharmacogenetics, rheu matoid
arthritis, -308G/A TNF-a gene polymorphism, -174G/C
IL-6 gene polymorphism 
(p=0.022, c2 test). Ta~nije, svi pacijenti sa kombinovanim
IL-6 -174GG / TNF-a -308GG genotipom bili su respon-
deri posle 12 meseci terapije etanerceptom.
Zaklju~ak: Studija pokazuje da bolesnici sa genotipovima
koji se povezuju sa manjom produkcijom TNF-a i IL-6
najbolje odgovaraju na terapiju etanerceptom.
Klju~ne re~i: etanercept, reumatoidni artritis, farmako -
genomika, -308G/A TNF-a genski polimorfizam, -174G/C
IL-6 genski polimorfizam
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Rheuma tology, Faculty of Medicine, University of
Belgrade, Serbia. The patients were treated with sub-
cutaneous etanercept, 50 mg once per week, in com-
bination with corticosteroids (33 cases) or other
DMARDs (methotrexate, 60 cases; sulphasalazine, 3
cases; lef lu nomide, 5 cases; chloroquine, 5 cases).
DMARDs and corticosteroid doses were maintained
at a stable concentration during follow-up. The
patients were studied before etanercept treatment
was started, and six and twelve months after the initi-
ation of eta nercept therapy. The clinical status was
evaluated by the tender joint count and swollen joint
count, Health Asses sment Questionnaire (HAQ)
score, and the Disease Activity Score in 28 joints
(DAS28). Labo ratory studies included measurement
of serum C-reactive protein (CRP) and rheumatoid
factor (RF) and anti-cyclic citrullinated peptides (CCP)
antibodies levels. The cli nical response was evaluated
according to the Euro pean League Against
Rheumatism (EULAR) response criteria (23). The
main outcome was an improvement in the DAS28
score, which is defined as a decrease of at least 1.2. 
The study was approved by the Ethics Commit -
tee at the Institute of Rheumatology, Faculty of
Medicine, Belgrade and was conducted according to
the Helsinki Declaration. All patients gave written
informed consent to participate in the study. 
Genotyping
The genotyping of the -308G/A TNF-a and
-174G/C IL-6 gene polymorphisms was performed by
a polymerase chain reaction restriction fragment
length polymorphism (PCR-RFLP) method. Genomic
leukocyte DNA was extracted from peripheral blood
with a QIAamp DNA Mini Kit (Qiagen). 
TNF-a
Primers: AGGCAATAGGTTTTGAGGGCCAT (for -
 ward) and ACACTCCCCATCCTCCCTGCT (reverse).
The forward primer sequence was altered (underlined
base) to generate a restriction site in the major allele.
The conditions for PCR reaction were: a denaturation
step at 94 °C for 5 min followed by 35 cycles (94 °C for
30 sec, 56 °C for 30 sec and 72 °C for 45 sec) and final
elongation step of 10 min at 72 °C. After digestion with
Nco I (MBI Fermentas, Vilnius, Lithuania) fragments
of the following length were obtained: for genotype GG
– 97+20 bp, GA – 117+97+20 bp and AA – 117 bp.
IL-6
A 525 bp fragment was amplified using the fol-
lowing primers: GGAGTCACACACTCCACCT (for-
ward) and CTGATTGGAAACCTTATTAAG (reverse).
Samples were subjected to a denaturation step at 94
°C for 5 min followed by 35 cycles. Each cycle was as
follows: 94 °C for 30 sec, 56 °C for 30 sec and 72 °C
for 45 sec; the last cycle was followed by a 10 min
incubation at 72°C. A 15 μL aliquot of the PCR-prod-
uct was digested at 37 °C for 2 h with Hin1 II (Fer -
mentas).
Genotyping was performed at the Institute of
Molecular Genetics and Genetic Engineering, Uni -
versity of Belgrade, Serbia.
Statistical analysis
Continuous variables were expressed as means
± SD of the values. Differences between the groups
were statistically evaluated by the independent sam-
ple T-test and One-Way ANOVA followed by the
Tukey test for post hoc comparisons. Chi-square test
or Fisher’s exact test were used to test group differ-
ences of proportions. Differences were considered to
be significant in all cases when p < 0.05. Data were
analysed using the SPSS for Windows 17.0 software
(SPSS, Inc, Chicago, IL, USA).
Results
Baseline characteristics of the patients 
The baseline characteristics of 73 patients,
before the first injection of etanercept, are summa-
rized in Table I. They were 48.10±11.67 (mean±SD)
years old, their disease duration was 8.83±7.36
(mean±SD) years and 86.3% were female. All
patients had active disease (mean DAS28±SD was
6.10±0.88; mean number of swollen and tender
joints±SD was 9.63±4.38 and 12.23±5.36, respec-
tively; mean CRP±SD was 21.15±25.72) and
showed functional disability (mean HAQ±SD was
1.06±0.81). Almost half of the patients (43.8%)
were rheumatoid factor positive and 75.1% were anti-
CCP antibody positive. Also in Table I, the baseline
characteristics of the patients according to IL-6 -174
and TNF-a-308 geno typic groups were presented.
Twenty-three patients had the IL-6 -174GG genotype
(31%), 41 (56.2%) had the IL-6 -174GC genotype,
and the remaining 9 (12.3%) had the IL-6 -174CC
genotype. The TNF-a-308GG genotype was detected
in 54 (74%) patients, whereas TNF-a -308GA and
AA genotype were found in 18 (24.7%) and 1 (1.4%)
patients, respectively, hence the patients with the
TNF-a-308GA and AA genotypes were placed in one
group. No significant differences were observed
between the three IL-6 genotypic groups or between
the two TNF-a genotypic groups at baseline with
regard to mean age, disease onset, disease duration,
RF and anti-CCP antibody status and the disease
activity and disability parameters, such as DAS28
and HAQ. A statistically significantly higher number
of swollen joints was observed in patients with the
-174CC genotype compared with those with GG or
GC genotype (CC vs. GG, p<0.05; CC vs. GC,
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p<0.05). No association between the combined IL-
6/TNF-a genotype and baseline demographics and
clinical and laboratory features of the patients was
detected (data not shown).
-174 IL-6 and -308 TNF-a gene polymor-
phisms and response to etanercept therapy
Clinical response to etanercept was determined
using the DAS28 improvement criteria. Good respon-
ders (after 6 and 12 months of treatment) were
defined, according to the EULAR criteria, as patients
whose DAS28 score improved by at least 1.2 points
and bad responders (nonresponders) were defined as
patients whose DAS28 score improved by less than
1.2 points (23). By these criteria, of the 73 patients,
62 (84.9%) and 57 (78.1%) were responders after 6
and 12 months of treatment, respectively. 
In accordance with our previous study (18), after
12 months of treatment the percentage of responders
was significantly increased in patients with the IL-6
-174GG genotype (95.7%) compared with those with
the GC (75.6%) or CC (44.4%) genotype (p=0.006
by Chi-square test) (Table II). On the other hand,
TNF-a genotype did not influence etanercept
response, as no significant difference in the percent-
age of DAS28 responders between patients with TNF-
a -308GG and GA/AA genotype was detected after
6 and 12 months of etanercept therapy. When we
analyzed patients according to their combined IL-
6/TNF-a genotypes, after 12 months of treatment all
patients carrying the combined IL-6 -174GG / TNF
-a-308GG genotype were responders, whereas the
percentage of responders was significantly decreased
in patients with other combination of IL-6/TNF-a
genotypes (83.3%, 78.6%, 69.2%, 44.4% for pa tients
with IL-6 -174GG / TNF-a -308GA and AA, IL-6
-174GC/TNF-a -308GG,IL-6 -174GC /TNF-a -308GA
and AA, IL-6 -174GG / TNF-a -308CC, respectively)
(p=0.022 by Chi-square test) (Table II). 
The mean values of DAS28 score improvement
did not significantly differ between IL-6 genotypic
groups or between TNF-a genotypic groups (Table



















Age, years 48.10±11.67 45.63±11.63 48.8±12.23 51.22±8.63 0.407 48.27±11.63 47.63±12.07 0.839
Women, 
no. (%) 63 (86.3%) 17 (73.9%) 38 (92.7%) 8 (88.9%) 0.108 47 (87%) 16 (84.2%) 0.714
Disease 
duration, years 8.83±7.36 8.04±7.74 9.37±7.56 8.33±5.85 0.781 8.44±6.28 9.92±9.91 0.457
Disease onset,
years 38.78±13.63 37.93±11.93 39.44±14.42 37.89±15.18 0.899 39.19±12.73 37.66±16.23 0.678
Tender joints, 
no. 12.23±5.35 11.91±5.32 11.73±5.00 15.33 ± 6.54 0.179 12.65±5.64 11.05±4.39 0.267
Swollen joints,
no. 9.63±4.38 9.35±4.73 8.98±3.57 13.33±5.38*
a,b 0.022 9.33±4.25 10.47±4.73 0.332
DAS28 score 6.10±0.88 6.14±0.84 6.03±0.91 6.28±0.92 0.716 6.07±0.88 6.19±0.92 0.607
HAQ score 1.06±0.81 1.14±0.98 1.02±0.78 1.06±0.34 0.853 0.95±0.65 1.32±0.92 0.170
Serum CRP,
mg/L 21.15±25.72 16.61±22.30 23.07±25.56 24.37±36.23 0.593 18.93±25.04 27.33±27.23 0.225
Positive RF (%) 43.8% 47.8% 41% 62.5% 0.523 47.1% 42.1% 0.711
Positive anti-CCP
ab (%) 72.1% 58.3% 75% 85.7% 0.391 78.1% 54.5% 0.241
Table I Baseline characteristics of the patients.
Values are mean ± SD unless otherwise indicated. DAS28 – Disease Activity Score in 28 joints; HAQ – Health Assessment
Questionnaire; CRP – C-reactive protein; RF – rheumatoid factor; anti-CCP ab – anti-cyclic citrullinated peptides antibody. P val-
ues were calculated using Chi-square test (for categorical variables) or One-Way ANOVA test and independent samples T-test (for
continuous variables); *p<0.05, aCC vs. GG, bCC vs. GC using One-Way ANOVA. 
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Table II IL-6 and TNF-a genotypes and etanercept therapy response.
Table III Improvement in DAS28 scores with etanercept therapy and polymorphisms of IL-6 (-174G/C) and TNF-a (-308G/A).
Genotype Patients, no.
After 6 months of treatment
p 
value









GG 23 20 (87) 3 (13)
0.803
22 (95.7) 1 (4.3)
GC 41 35 (85.4) 6 (14.6) 31 (75.6) 10 (24.4) 0.006**
CC 9 7 (77.8) 2 (22.2) 4 (44.4) 5 (55.6)
-308 TNF-a
GG 54 47 (87) 7 (13)
0.397
43 (79.6) 11 (20.4)
0.590
GA & AA 19 15 (78.9) 4 (21.1) 14 (73.7) 5 (26.3)
Combined IL-6/TNF-a
GG/GG 17 16 (94.1) 1 (5.9)
0.548
17 (100) 0 (0)
0.022*
GG/GA & AA 6 4 (66.7) 2 (33.3) 5 (83.3) 1 (16.7)
GC/GG 28 24 (85.7) 4 (14.3) 22 (78.6) 6 (21.4)
GC/GA & AA 13 11 (84.6) 2 (15.4) 9 (69.2) 4 (30.8)
CC/GG 9 7 (77.8) 2 (15.4) 4 (44.4) 5 (55.6)
P values were calculated using Chi-square test; *p<0.05, **p<0.01.
Values are mean ± SD. DAS28 – Disease Activity Score in 28 joints. P values were calculated using One-Way ANOVA test and
independent sample T-test.
Genotype Improvement in DAS28scores at month 6 p value
Improvement in DAS28


















GG/GA & AA 1.80±1.35 2.86±0.82
GC/GG 2.06±0.92 2.47±1.39
GC/GA & AA 1.86±0.83 2.90±1.31
CC/GG 1.97±1.23 2.21±0.36
magnitude of DAS28 improvement between the com-
bined IL-6/TNF-a genotypes (Table III). 
Discussion
We analysed the effects of - 308G/A TNF-a and
-174G/C IL-6 promoter polymorphisms on the res -
ponse to etanercept in RA patients with the aim of
searching for biomarkers to optimize the use of anti-
TNF-a therapy.
Several studies have investigated the relation -
ship between the -308G/A TNF-a poly morphism and
disease activity or response to anti-TNF-a treatment in
RA patients (9–13). Accordingly (10, 11, 13), in our
cohort of RA patients, association between the TNF-
a -308G/A polymorphism and clinical manifestations
or severity of RA was not found. This could be inter-
preted either as an absence of or a weak, and insuffi-
cient to be detected, influence of this polymorphism
on the production of TNF-a. Indeed, it has been
reported that other functional SNPs of the TNF-a
promoter may interact together with -308G/A poly-
morphism to determine the overall activity of the
TNF-a gene (24). However, although in these pre -
vious studies (9, 11–13) an association of TNF-a
-308G/A with response to anti-TNF-a therapy was
shown, we found no difference in the proportions of
responders between TNF-a -308G/A genotypes after
6 and 12 months of etanercept therapy. In agreement
with our finding, in a recent meta-analysis (16), which
analysed 12 studies plus unpublished data from a
total of 426 Dutch patients suffering from RA, asso-
ciation of -308G/A TNF-a polymorphism with differ-
ent response to anti-TNF-a therapy was not shown.
The authors suggested that the relatively small sam-
ple size, in previous papers and meta-analyses, is the
cause for the association found between -308G/A
TNF-a polymorphism and response to TNF-a blockers. 
It is known that the systemic effects of etaner-
cept may be the consequence of the crucial role of
TNF-a in the complex cytokine network regulating
immune and inflammatory responses. Specifically,
TNF-a stimulates transcription of the IL-6 gene (25)
and induces the secretion of IL-1 and IL-6 (20).
Moreover, via IL-12, TNF-a induces the secretion of
IFN-g (26), which is primarily produced by Th1 cells
and augments both transcription and mRNA stability
of proinflammatory cytokines, including IL-6 in
monocytes and macrophages (27). IL-6, IL-1 and
IFN-a in turn stimulate the release of TNF-a, thus
perpetuating a vicious circle of chronic inflammation
(28). Thus, the blockade of TNF-a by etanercept
induces decrease in inflammatory cytokine signalling
downstream of TNF-a and interrupts a positive
feedback loop of TNF-a production. Having all the
aforementioned in mind, investigation of the influ-
ence of functional genetic polymorphisms of
cytokines downstream of TNF-a, such as IL-6, as well
as their interactions on the response to etanercept
seems to be reasonable. 
In accordance with our previous data (18), RA
patients with the IL-6 -174GG genotype, known to
have lower serum concentrations of IL-6 (8), respond-
ed to etanercept better than patients with the GC or
CC genotype. When we analyzed patients according
to their combined IL-6/TNF-a genotypes, in this study
we found that all carriers of the  combined IL-6
-174GG / TNF-a -308GG genotype were DAS28
res ponders after 12 months of therapy. This finding is
not surprising since the G allele of -174G/C IL-6 and
A allele of -308G/A TNF-a polymorphisms are linked
to low and high production of IL-6 and TNF-a,
respectively, so in these subjects the lowest secretion
of the given cytokines was expected (7, 5). It should
be noted that treatment outcome was significantly
better in patients with the IL-6 -174GG / TNF-a
-308GG combined genotype than in patients carrying
at least one allele associated with increased cytokine
production. This finding points to the importance of
combined, rather than single analysis of the cytokine
genotypes to get a more accurate picture of treat-
ment response. Nevertheless, the treatment outcome
in the combined IL-6 -174GG / TNF-a -308GG
genotype was not statistically better than that
obtained after single analysis of the gene encoding
IL-6, since the patients with the combined IL-6
-174GG/TNF-a -308GA and AA genotype were
highly represented among the responders. Thus, it
seems that IL-6 genotyping in RA patients at the
onset of the disease could be sufficient to identify
suitable candidates for anti-TNF-a blockers.
There is significant variation in allele frequencies
among human populations. IL-6 -174G/C polymor-
phism is the most common in European (35%–50%),
less common in Indian (12.6%–14.5%) and the least
common in Asian and African populations (close to
0%) (30, 31). TNF-a -308G/A polymorphism is, also,
more frequent in European and Indian populations
(10%–23%) and less frequent in Asian (2%–9%) and
African populations (7%–11%) (29, 30). Therefore,
independent pharmacogenetic studies should be per-
formed for the major human populations to deter-
mine the influence of IL-6 -174G/C and TNF-a -308
G/A polymorphisms on the efficacy of etanercept. 
A limitation of the work is the small sample size.
Namely, although etanercept is very effective in treat-
ing RA, its cost and strict inclusion criteria are often
the main reasons why the published observations in
RA patients, as well as our study, generally have a
small sample size. 
In conclusion, we have shown that genetic vari-
ation at the functional -308G/A TNF-a polymor-
phism does not influence disease activity or response
to etanercept therapy in patients with RA. Although
the single analysis of the TNF-a genotype did not
show a significant influence on the etanercept res -
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ponse, analysis of the combined IL-6/TNF-a geno-
type demon strated that carriers of the IL-6 -174GG /
TNF-a -308GG genotype respond to etanercept bet-
ter than patients with other combined IL-6/TNF-a
genotypes. Since all the carriers of the combined IL-6
-174GG / TNF-a -308GG genotype were responders,
it can be assumed that RA patients who are genetical-
ly low TNF-a and IL-6 producers may be the most
suitable candidates for anti-TNF-a therapy. Validation
of these findings in independent cohorts is needed.
Pharmacogenomic testing is currently required
before administering maraviroc (for human immuno -
deficiency virus treatment), cetuximab (for colorectal
cancer treatment), trastuzumab (for breast cancer
treatment), and dasatinib (for acute lymphoblastic
leukemia treatment) (31). In such specific situations,
pharmacogenetic testing is done to determine if an
individual is likely to benefit from the specific thera-
peutic agent, rather than to tailor the dosage.
Pharma cogenetics in rheumatology is still in its infan-
cy, but it is a fast-growing field. Continued research
should soon make individualized drug therapy in the
rheumatic diseases a reality (32, 33). Avoiding the
pharmacy costs of treatment failures or severe
adverse events would be a logical rationale to justify
the additional medical costs of this type of testing.
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